Trump’s proposed tariffs to impact US pharma FDI in Canada, Mexico, China and Europe, reveals GlobalData - GlobalData

Almomento.Mx

Factuality

Ownership

MEXICO CITY.- As one of his first trade measures, Donald Trump recently signed orders to impose 25% tariffs on products from Mexico and Canada and 10% on products from China. Since then and even the realization of these measures, there are several points to highlight: 1. During his presidential campaign, China was the number 1 enemy of the United States. Why was it then decided to apply lower tariffs to this country than to Canada and Mexico? An…

swr.online

Factuality

Ownership

Because the U.S. market is a "very important" one, pharmaceutical companies fear from BW tariffs of President Trump. Moreover, the high energy costs of the industry make it possible to create.

GlobalData

Factuality

Ownership

Trump’s proposed tariffs to impact US pharma FDI in Canada, Mexico, China and Europe, reveals GlobalData - GlobalData

The pharmaceutical industry is preparing for major disruptions following Trump’s tariff announcement—25% on imports from Canada and Mexico (both paused for 30 days) and 10% on China. These tariffs could worsen drug shortages, raise prices, and push manufacturers to reconsider their market strategies. Additionally, the proposed tariffs are expected to impact pharmaceutical foreign direct investment (FDI) by the US in those countries, including Eu…